Phase III
The drug was being evaluated in 237 adults with locally advanced or metastatic non-small cell lung cancer whose disease progressed while on or after previous platinum-based chemotherapy and checkpoint inhibitor immunotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 9, 2021.
The findings from the late-stage trial of Vyrologix have not been published, but CytoDyn said it is preparing a manuscript of the study data for submission.
It was another busy week for clinical trial announcements. Here’s a look.
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
The topline data from the BRAVE-AA2 study in 546 adults showed both 2 mg and 4 mg doses of Olumiant regrew hair in adult patients with more than 50% scalp hair loss, compared with placebo.
The study of VIR-7831, which is a dual-action SARS-CoV-2 monoclonal antibody, was recommended to be closed to enrollment by an independent data monitoring board, stating that “there were no reported safety signals, sensitivity analyses of the available data raised concerns about the magnitude of potential benefit.”
Eye disease company Oyster Point announced the New Drug Application for its dry eye disease therapy OC-01, submitted in December, has been accepted for regulatory review on the back of positive Phase III data.
Cancer therapy company Athenex suffered a regulatory setback with the receipt of a complete response letter from the U.S. Food and Drug Administration.
In a fourth quarter 2020 financial results announcement made on Monday, Inovio Pharmaceuticals said it has completed enrollment of 400 participants in its Phase II segment of the INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) Phase II/III trial.
PRESS RELEASES